180 Life Sciences Corp.
ATNF
$1.08
-$0.09-7.69%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 576.40K | 1.22M | 1.56M | 1.49M | 2.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 979.10K | 1.85M | 2.09M | 1.45M | 3.54M |
| Operating Income | -979.10K | -1.85M | -2.09M | -1.45M | -3.54M |
| Income Before Tax | -836.70K | 11.80K | -1.07M | -1.23M | -12.61M |
| Income Tax Expenses | -- | -- | -- | -4.40K | -2.35M |
| Earnings from Continuing Operations | -836.70K | 11.80K | -1.07M | -1.23M | -10.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -836.70K | 11.80K | -1.07M | -1.23M | -10.27M |
| EBIT | -979.10K | -1.85M | -2.09M | -1.45M | -3.54M |
| EBITDA | -965.20K | -1.82M | -2.07M | -1.43M | -3.51M |
| EPS Basic | -0.85 | 0.01 | -1.68 | -1.97 | -24.53 |
| Normalized Basic EPS | -0.56 | -0.10 | -1.05 | -1.44 | -5.30 |
| EPS Diluted | -0.85 | 0.01 | -1.68 | -1.97 | -24.53 |
| Normalized Diluted EPS | -0.56 | -0.10 | -1.05 | -1.44 | -5.30 |
| Average Basic Shares Outstanding | 980.60K | 919.10K | 638.30K | 622.90K | 418.50K |
| Average Diluted Shares Outstanding | 980.60K | 919.10K | 638.30K | 622.90K | 418.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
